Day: November 10, 2022

WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2022 before the opening of the U.S. financial markets on Monday, November 14, 2022. The Company will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions. Conference Call and Webcast InformationEvent: Biofrontera Inc. Third Quarter 2022 Financial Results and Business Update Conference CallDate: Monday, November 14, 2022Time: 11:00 a.m. Eastern timeConference call: 1-877-877-1275 (U.S.)1-412-858-5202 (international)Webcast: Live and 90-day replay webcast are...

Hacktivism, deepfakes, attacks on business collaboration tools, new regulatory mandates, and pressure to cut complexity will top organizations’ security agendas over coming year SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, has released its cyber-security predictions for 2023, detailing the key security challenges that organizations will face over the next year. Cyberattacks across all industry sectors increased by 28% in the third quarter of 2022 compared to 2021, and Check Point predicts a continued sharp rise worldwide, driven by increases in ransomware exploits and in state-mobilized hacktivism driven by international conflicts. At the same time, organizations’ security teams will face growing pressure as...

Innofactor Plc Announcement 10.11.2022          Innofactor Plc: Share Repurchase 10.11.2022       In the Helsinki Stock Exchange         Trade date 10.11.2022  Bourse trade Buy  Share IFA1V  Amount 12,000 SharesAverage price/ share 0.9535 EURTotal cost 11,442.00 EUR          Innofactor Plc now holds a total of 1 011 200 sharesincluding the shares repurchased on 10.11.2022          On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_10.11_trades

Series RIKV 23 0118 RIKV 23 0315ISIN IS0000034361 IS0000034551Maturity Date 01/18/2023 03/15/2023Auction Date 11/14/2022 11/14/2022Settlement Date 11/16/2022 11/16/2022On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bills in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bills must be received by the Central Bank before 14:00 on the Settlement Date and the Bills will be delivered in electronic form on the same day. Further reference is made to the General Terms of Icelandic Treasury bills and General Terms of Auction for Treasury bills on the Government Debt Management website. For additional information please contact Oddgeir Gunnarsson, Government Debt Management, at +354 569 9635.

AAHKS Innovation Award Presentation Nick van der Walt, Selene van der Walt, Chad Rains, Jonathan Nielsen and Louie Vogt accepted the AAHKS Industry Innovation Award. They are joined by Dr. Lucian Warth and Dr. Bryan D. Springer, President of AAHKS.Wilmington, DE, Nov. 10, 2022 (GLOBE NEWSWIRE) — Today, Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that the company’s ARVIS® Augmented Reality Surgical Guidance System received the Industry Innovation Award at the this year’s American Academy of Hip and Knee Surgeons (AAHKS) Annual Meeting. This annual award recognizes cutting-edge innovation in products, procedures and services in the field of Hip and Knee Arthroplasty. ARVIS is the only FDA-cleared proprietary, real-time, hands-free augmented reality (AR) technology engineered for...

Manhattan, NY, Nov. 10, 2022 (GLOBE NEWSWIRE) — Healixa, Inc. (OTC Pink: EMOR) (“Healixa”, or the “Company”), a technology company focusing on building and acquiring innovative and disruptive technologies in the health-tech, clean water and green-tech industries today announces that it has signed its initial revenue contracts for its AdvocateCare™ subsidiary. “Our company is excited to have such a strong opportunity in this very lucrative area. Our approach to Care Management is unique since we are focused on providing proactive holistic preventative care and wellness solutions with cutting edge technology, and analytics which produce enhanced care models and reduce costs of care making today’s announcement very significant” said Healixa’s CEO Ian Parker. AdvocateCare™ uniquely combines personalized...

SPARTANBURG, S.C., Nov. 10, 2022 (GLOBE NEWSWIRE) — Denny’s Corporation (the “Company”) (NASDAQ: DENN), owner and operator of Denny’s Inc. (“Denny’s”) and Keke’s Inc. (“Keke’s”), today announced that the Company will participate in the Stephens Annual Investment Conference in Nashville, Tennessee. On Thursday, November 17, 2022, the Company will conduct investor meetings with a presentation by Robert Verostek, Chief Financial Officer, at 1:00 p.m. Central Time. Investors and interested parties may listen to a live audio webcast of the event which will be available online in the Investor Relations section of the Company’s website at investor.dennys.com. A replay of the event webcast will be available for approximately 90 days following the event. Investors and interested...

Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European CommissionFirst and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe Strong immune response against all tested variants of concern Ready to supply for fall-winter COVID-19 vaccination campaigns in EuropeParis, November 10, 2022. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by the European Commission, as a booster for the prevention of COVID-19 in adults 18 years of age and older. Designed to provide broad protection against multiple variants, the protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK’s pandemic adjuvant. VidPrevtyn Beta is indicated...